跳至主要内容
临床试验/ACTRN12612001194853
ACTRN12612001194853已完成3 期

The CNS sub-study of a randomised, double-blind, placebo-controlled, clinical trial to compare the safety and efficacy of reduced dose efavirenz (EFV) with standard dose EFV plus 2N(t)RTI in antiretroviral-naive HIV-infected individuals over 96 weeks

Kirby Institute, University of New South Wales0 个研究点目标入组 40 人开始时间: 2012年11月13日最近更新:

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
16 Years 至 o limit(—)
性别
All

入选标准

  • All subjects entering into the main study protocol at participating centres will be eligible to enter this sub-study

排除标准

  • Existing neurological disease which in the opinion of the
  • investigator would be a contra-indication to lumbar
  • puncture examination
  • CNS opportunistic infections in the past 12 weeks
  • Bacterial or viral meningitis in the past 12 weeks
  • Head injury requiring medical assessment in the past 12 weeks

研究者

发起方
Kirby Institute, University of New South Wales

相似试验